Edgewise Therapeutics, Inc. Profile
Industry
BiotechnologySector
HealthcareNumber of Employees
88Edgewise rapeutics's Business Model
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.
About Edgewise rapeutics
Website: https://www.edgewisetx.com
CEO (Chief Executive Officer): Dr. Kevin Koch Ph.D.
IPO date: 2021-03-26
Contact
Country: US
Address: 3415 Colorado Avenue
City: Boulder
State: CO
Phone: 303 735 8373
Zip Code: 80303
Other
CIK: 0001710072
ISIN: US28036F1057
CUSIP: 28036F105
Disclaimer: The data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by our third party API www.financialmodellingprep.com, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore, Discounting Cash Flows Inc. doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Discounting Cash Flows Inc. or anyone involved with Discounting Cash Flows Inc. will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
